Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
New Nordic Healthbrands ABFRA:N9X +2.73%71 Debt-to-EBITDA is 0.95 as of Jun. 2026, which is 400% above its 10-year median of 0.19. GuruFocus rates FRA:N9X with a GF Score™ of 71/100 and a GF Value™ of €1.74. The stock has 3 warning signs investors should review. Among 1,563 Consumer Packaged Goods companies, New Nordic Healthbrands AB ranks worse than 51.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for New Nordic Healthbrands AB's Debt-to-EBITDA or its related term are showing as below:
FRA:N9X'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -25.94 Med: 0.19 Max: 2.23
Current: 2.23
During the past 13 years, the highest Debt-to-EBITDA Ratio of New Nordic Healthbrands AB was 2.23. The lowest was -25.94. And the median was 0.19.
FRA:N9X's Debt-to-EBITDA is ranked worse than 51.89% of 1563
companies
in the Consumer Packaged Goods industry
Industry Median: 2.08
vs FRA:N9X: 2.23
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
New Nordic Healthbrands AB Debt-to-EBITDA Related Terms
New Nordic Healthbrands AB Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:N9X vs KHC, GIS, MKC: Debt-to-EBITDA Comparison
For the Packaged Foods subindustry, New Nordic Healthbrands AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Nordic Healthbrands AB Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, New Nordic Healthbrands AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where New Nordic Healthbrands AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
New Nordic Healthbrands AB (FRA:N9X) has a Debt-to-EBITDA of 0.95 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on New Nordic Healthbrands AB. This is 400% above median its historical median of 0.19. According to the industry distribution chart, New Nordic Healthbrands AB ranks #811 out of 1563 companies in the Consumer Packaged Goods industry, placing it in the top 51.9%.
Is New Nordic Healthbrands AB's Debt-to-EBITDA too high?
New Nordic Healthbrands AB's current Debt-to-EBITDA of 0.95 is 400% above median its 10-year median of 0.19. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.08. New Nordic Healthbrands AB's value of 0.95 is 54.3% below this industry median. Based on the distribution chart, New Nordic Healthbrands AB ranks #811 out of 1563 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, New Nordic Healthbrands AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does New Nordic Healthbrands AB's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, New Nordic Healthbrands AB ranks #811 out of 1563 companies for Debt-to-EBITDA. This places New Nordic Healthbrands AB in the lower half of its industry. The industry median Debt-to-EBITDA is 2.08. New Nordic Healthbrands AB's value of 0.95 is 54.3% below this benchmark. While the company's 10-year median is 0.19 vs. the industry median of 2.08, New Nordic Healthbrands AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.08, based on 1,563 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Nordic Healthbrands AB's current Debt-to-EBITDA of 0.95 is 54.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on New Nordic Healthbrands AB. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Nordic Healthbrands AB's current Debt-to-EBITDA is 0.95, which is 400% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Nordic Healthbrands AB stock overvalued right now?
New Nordic Healthbrands AB (FRA:N9X) has a current Debt-to-EBITDA of 0.95. The stock's GF Value™ is €1.74, compared to a current price of €1.51 — trading 13.5% below its estimated fair value. The current Debt-to-EBITDA is 0.95, which is 400% above median its 10-year median of 0.19 and 54.3% below the Consumer Packaged Goods industry median of 2.08. New Nordic Healthbrands AB's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For New Nordic Healthbrands AB (FRA:N9X), the current Debt-to-EBITDA is 0.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Nordic Healthbrands AB (FRA:N9X) Overvalued in 2026?
Based on GuruFocus' analysis, New Nordic Healthbrands AB stock appears to be undervalued.
The current stock price of €1.51 is trading 13.5% below its estimated GF Value™ of €1.74.
Key valuation signals for FRA:N9X:
Debt-to-EBITDA: 0.95 (400% above median its 10-year median of 0.19)
GF Value™: €1.74 vs. price of €1.51 (13.5% below fair value)
Industry Position: 54.3% below the Consumer Packaged Goods median (#811 of 1563)
No single metric tells the full story. See the FRA:N9X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Nordic Healthbrands AB develops herbal supplements, herbal remedies, and personal care products to satisfy specific health and beauty needs. The products are sold in North America, Europe, and Asia. Some products sold are Active legs, Active Liver, Apple Cider, Chili Burn, Clear brain, Ear tone, Equazen, Frutin gastro gel, Hair Gro, Hair Volume, Kilo trim, and Melissa Dream. Maximum revenue is generated from the Nordic region.
71GF Score
Get the complete analysis for FRA:N9X
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N9X has been successfully added to your 
